Mendus AB presented survival data based on the completed active study period and long-term follow-up to date from the Company’s ADVANCE II clinical trial at the 64th American Society of Hematology Annual Meeting (ASH). ADVANCE II is a Phase 2 monotherapy trial evaluating DCP-001 as a maintenance therapy in acute myeloid leukemia (AML) for patients brought into complete remission through chemotherapy, but with measurable residual disease (MRD).
Mendus hosted a webcast to discuss the combined data sets presented at ASH on December 13, 2022. The replay can be accessed via: https://edge.media-server.com/mmc/p/fbg3u4we